Global Retirement Partners LLC Grows Stock Holdings in Stryker Corporation $SYK
Global Retirement Partners LLC significantly increased its stake in Stryker Corporation (NYSE:SYK) by 54.6% in the fourth quarter, bringing its total holdings to 10,763 shares valued at approximately $3.78 million. Institutional investors collectively own 77.09% of Stryker's stock, with several other firms also boosting their positions. Despite the increased institutional interest, a Stryker VP recently sold a large portion of her shares, and the company's latest earnings missed analyst expectations, although revenue increased and a dividend of $0.88 per share was announced.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Stryker Corporation (SYK) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Stryker Corporation (SYK) following a significant drop in its stock price. This decline occurred after the company disclosed that a March 2026 cyberattack "meaningfully" affected its first-quarter 2026 operating results and growth. Shareholders are encouraged to join the investigation, which seeks to recover losses on a contingency fee basis.
Stryker Corp. stock underperforms Thursday when compared to competitors
Stryker Corp. (SYK) shares fell by 2.49% on Thursday, closing at $313.50, despite a generally positive trading session for the broader stock market. This decline broke a seven-day winning streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average both saw gains on the same day.
Stryker’s chief accounting officer to retire
William Berry Jr., Stryker's chief accounting officer, is set to retire on September 1, 2026. His role will be absorbed by Emily Baculik, the current corporate controller, who will take on the additional responsibilities. Berry will continue in an advisory capacity until August 2027, maintaining his salary and bonus eligibility, while Baculik will receive a salary increase and long-term incentive plan consideration upon her promotion.
Bronstein, Gewirtz & Grossman, LLC Encourages Stryker Corporation (SYK) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Stryker Corporation (NYSE:SYK) securities following a significant stock drop. The investigation stems from Stryker's April 2026 announcement of a cyberattack in March 2026 that "meaningfully" affected its first-quarter results. Following this news, Stryker's stock price fell by $20.40 per share, or 6.47%, to close at $294.73 on May 1, 2026.
Rathbones Group PLC Grows Stock Position in Stryker Corporation $SYK
Rathbones Group PLC significantly increased its stake in Stryker Corporation by 647.9% in the fourth quarter, holding 219,265 shares valued at approximately $77.1 million. Despite this, Stryker reported mixed quarterly results, missing EPS and revenue estimates, although revenue increased by 2.6% year-over-year. Analyst sentiment remains largely positive, with 16 Buy ratings and 6 Hold ratings, yet TD Cowen recently downgraded the stock to Hold.
Stryker Corp. stock (US8636671013): Growth story continues after strong results
Stryker Corp. (SYK) continues to be a focus for U.S. healthcare investors due to solid financial results and a recent acquisition in the vascular segment. The company's strong position in orthopedics, surgical equipment, and neurotechnology positions it well to capitalize on hospital spending trends and procedure volumes. While the growth story appears intact, investors will monitor future updates for successful integration of acquisitions and sustained performance.
Stryker Announces Chief Accounting Officer Retirement and Successor
Stryker (SYK) announced the retirement of its Chief Accounting Officer, William E. Berry, Jr., effective September 1, 2026. He will continue as an advisor to the CFO until August 15, 2027. Emily Baculik, the current Vice President and Corporate Controller, will succeed him, ensuring a structured leadership transition within the company's finance function.
Stryker (SYK) appoints Emily Baculik CAO as Berry shifts to advisor
Stryker Corporation announced that Emily Baculik will succeed William E. Berry, Jr. as Vice President and Chief Accounting Officer effective September 1, 2026. Berry will transition to an advisor role until August 2027, maintaining his current salary and bonus eligibility for 2026. Baculik's compensation will include an increased base salary, a target bonus, and a proposed long-term incentive grant of approximately $400,000.
Medtronic to buy SPR Therapeutics for about $650M
Medtronic announced its agreement to acquire SPR Therapeutics for $650 million in cash, marking its third major acquisition this year. This deal will expand Medtronic's neuromodulation business by adding SPR Therapeutic's Sprint peripheral nerve stimulation device, which treats chronic pain without requiring a permanent implant. The acquisition is expected to close within the first half of Medtronic's 2027 fiscal year, pending regulatory approvals.
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast
West Pharmaceutical Services has announced that it has fully restored operations after a cybersecurity attack earlier this month. The company does not anticipate any material impact on its 2026 financial outlook and continues its investigation, having found no further unauthorized access. Analysts are encouraged by the company's quick return to normal operations and ability to offset disruptions.
Stryker Corp. stock outperforms competitors on strong trading day
Stryker Corp. (SYK) shares rose 1.18% to $321.49, outperforming the broader market which also saw gains with the S&P 500 up 1.08% and the Dow Jones Industrial Average up 1.31%. This marks the seventh consecutive day of gains for Stryker's stock.
Medtronic to spend $650M on 60-day nerve therapy for chronic pain
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash. This acquisition will add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, aiming to expand care options for chronic pain sufferers. The deal is expected to close in the first half of Fiscal 2027, subject to regulatory approvals.
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Medtronic plc announced its intent to acquire SPR Therapeutics, Inc. for approximately $650 million. This acquisition will enhance Medtronic's Neuromodulation portfolio by adding temporary peripheral nerve stimulation (PNS) technology, specifically the SPRINT® PNS System, to provide earlier intervention options for chronic pain sufferers. The transaction is expected to close in the first half of Medtronic's Fiscal Year 2027.
PNC Financial Services Group Inc. Lowers Stock Position in Stryker Corporation $SYK
PNC Financial Services Group Inc. significantly reduced its stake in Stryker Corporation (NYSE:SYK) by 3.2% in the fourth quarter, selling over 32,000 shares. Despite this, several other institutional investors increased their positions in the medical technology company, which recently reported an earnings miss for its last quarter but announced a quarterly dividend. Analysts currently rate Stryker as a "Moderate Buy" with an average target price of $395.48.
Stryker Corporation $SYK Stock Position Increased by Atle Fund Management AB
Atle Fund Management AB increased its stake in Stryker Corporation (NYSE:SYK) by 17.9% in the fourth quarter, holding 26,835 shares valued at $9.43 million, making it the fund's 11th largest position. Despite this accumulation and a "Moderate Buy" consensus rating from analysts, Stryker recently missed earnings expectations, reporting lower EPS and revenue than estimated. The company also declared a quarterly dividend of $0.88 per share, but some analysts have lowered their price targets.
Stryker Corp. stock (US8636671013): acquisition news and medical device growth story
Stryker Corp. is expanding its vascular portfolio with the planned acquisition of Amplitude Vascular Systems for up to $835 million, demonstrating its strategy to grow through targeted deals in promising therapy areas. The medical technology group, known for its orthopedics, surgical equipment, and neurotechnology, aims to strengthen its solutions for peripheral vascular interventions. This move underscores Stryker's continuous investment in innovation and acquisitions to maintain its relevance in the competitive medical device industry, serving hospital and outpatient care structures globally.
Stryker’s Amplitude Deal Extends Peripheral Vascular Reach And Investor Debate
Stryker (NYSE:SYK) has announced its acquisition of Amplitude Vascular Systems for up to $835 million, integrating next-generation hydraulic intravascular lithotripsy technology into its peripheral vascular portfolio. This strategic move aims to enhance Stryker's presence in treating peripheral arterial disease. The deal has generated investor interest, particularly given Stryker's recent mixed stock performance, highlighting a push towards business expansion and capital allocation decisions.
BioStar Capital-Backed Amplitude Vascular Systems’ $835M Acquisition by Stryker Reflects Strength of Michigan’s Medtech Ecosystem
BioStar Capital-backed Amplitude Vascular Systems (AVS) was acquired by Stryker for up to $835 million, highlighting Michigan's strong medtech ecosystem. AVS developed a hydraulic intravascular lithotripsy platform for calcified peripheral arterial disease, a technology originating from the University of Michigan. This acquisition marks another successful exit for BioStar Capital, a firm known for investing in transformative medical technologies.
Stryker hit with new hip replacement lawsuit in Oregon
An Oregon woman is suing Stryker Orthopaedics, alleging their Trident System hip replacement device was defective and caused her significant pain and bone loss. This lawsuit adds to dozens of similar cases in Oregon and hundreds nationwide against the company, which has previously issued recalls and received FDA warning letters regarding its products. Stryker has paid out at least $2 billion in settlements for various joint replacement technologies.
Robotics expert Brian Miller on product development, AI and what he learned at Intuitive
Brian Miller, former Intuitive EVP and chief digital officer, shares insights on product development, understanding customer needs, and the role of AI in surgical robotics, drawing from his extensive experience. Now CEO of Sovato, Miller emphasizes the importance of critical thinking, deep customer observation, and responsible use of AI and data in medical device innovation. He also touches on making the most of intraprocedural data and addressing potential "deskilling" concerns with advanced technologies.
Stryker Corp. stock underperforms Tuesday when compared to competitors despite daily gains
Shares of Stryker Corp. (SYK) gained 1.45% to $317.75 on Tuesday, extending its winning streak to a sixth consecutive day. Despite these daily gains, the stock underperformed compared to its competitors, as the broader market, including the S&P 500 and Dow Jones Industrial Average, experienced a decline.
Is Enovis’ Improving Q1 2026 Results And Reaffirmed Outlook Altering The Investment Case For ENOV?
Enovis Corporation reported improving Q1 2026 results with reduced net loss and reaffirmed its 2026 revenue outlook of US$2.31 billion to US$2.37 billion. This indicates progress in operational performance and management confidence, despite historical losses and complexities from acquisitions. The article suggests these developments support the near-term catalyst of better execution, but investors should remain aware of ongoing integration challenges and potential delays.
Stryker’s $835 Million AVS Deal Highlights Growing Role of Michigan’s Medtech Development Pipeline
Stryker's acquisition of Amplitude Vascular Systems (AVS) for up to $835 million highlights Michigan's strong medical technology ecosystem and the increasing value of pre-FDA approved vascular intervention platforms. The deal gives Stryker access to AVS's hydraulic intravascular lithotripsy technology, designed to treat calcified peripheral arterial disease, expanding Stryker's peripheral vascular portfolio with a focus on minimally invasive cardiovascular technologies. BioStar Capital played a significant role in AVS's development, emphasizing technologies that address unmet needs and improve clinical workflows, with AVS's technology originating from research at the University of Michigan.
Resona Asset Management Co. Ltd. Trims Stock Holdings in Stryker Corporation $SYK
Resona Asset Management Co. Ltd. reduced its holdings in Stryker Corporation (NYSE:SYK) by 3.6% in the fourth quarter, selling 3,795 shares and now owning 102,593 shares valued at $36.08 million. Other hedge funds also adjusted their stakes, with most increasing their positions, while a Stryker VP recently sold a significant amount of shares. The medical technology company's stock shows a debt-to-equity ratio of 0.62 and recently announced a quarterly dividend of $0.88 per share.
Henry Schein stock (US42548G1040): dental distributor in focus after latest quarterly update
Henry Schein, a major dental and medical distributor, recently released new quarterly figures and an updated outlook, drawing investor attention. The article examines the company's business model, key revenue drivers in its dental and medical segments, and the impact of factors like inflation and procedure volumes on its performance. It concludes that while Henry Schein maintains a strong position through recurring sales and technology offerings, it faces ongoing challenges from economic cycles and competitive pricing.
Michigan medtech startup draws $835M Stryker buyout deal
Stryker (NYSE: SYK) has acquired Amplitude Vascular Systems (AVS) for up to $835 million, integrating AVS's hydraulic intravascular lithotripsy technology for treating calcified peripheral arterial disease into its peripheral vascular portfolio. The deal highlights Michigan's strong medtech ecosystem, as all three involved companies—BioStar Capital, AVS, and Stryker—have significant ties to the state. AVS's Pulse System offers a safer and more effective alternative to existing treatments, utilizing CO₂-generated pressure waves delivered via a balloon catheter.
BioStar Capital-Backed Amplitude Vascular Systems’ $835M Acquisition by Stryker Reflects Strength of Michigan’s Medtech Ecosystem
BioStar Capital, a venture capital firm, announced the pre-FDA acquisition of its portfolio company, Amplitude Vascular Systems (AVS), by Stryker for up to $835 million. AVS developed a next-generation hydraulic intravascular lithotripsy platform for treating calcified peripheral arterial disease, a condition affecting 1 in 20 U.S. adults. This acquisition highlights the strength of Michigan's medtech ecosystem, as all three companies—BioStar Capital, AVS, and Stryker—have strong ties to the state.
Stryker Corp. stock (US8636671013): earnings momentum and hospital demand keep medical device giant in focus
Stryker Corp. remains a key focus for Wall Street due to strong demand for orthopedic implants and surgical equipment, reflecting robust hospital procedure volumes and capital spending. The medical device giant reported solid first-quarter 2026 revenue growth and higher adjusted earnings per share, driven by sustained procedure volumes in orthopedics and trauma. Stryker's stock offers US investors exposure to healthcare trends, including hospital capacity, reimbursement policies, and innovation in medical technologies, with its performance influenced by both company-specific execution and broader market dynamics.
J&J Has 'No Intention' of Giving Up IVL Market Leadership
Johnson & Johnson's subsidiary, Shockwave Medical, is asserting its continued dominance in the Intravascular Lithotripsy (IVL) market with the global launch of its fifth-generation C2 Aero system. Despite increasing competition from other major medical device companies, Shockwave's Chief Medical Officer, Nick West, emphasizes their commitment to market leadership, citing extensive clinical evidence, a robust reimbursement framework, and continuous R&D with plans for annual product launches. The company differentiates itself by defining true IVL as energy-based and focusing on enhanced deliverability and patient outcomes, even exploring new applications in carotid and structural heart diseases.
Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication
Stryker, through its recently acquired Amplitude Vascular Systems (AVS) division, has enrolled the first patient in a first-in-human study for its pulsatile intravascular lithotripsy (PIVL) therapy. The POWER CAD I study will evaluate the feasibility of the Pulse IVL system in treating severely calcified coronary arterial disease, with primary endpoints assessed at 30 days. The AVS IVL platform uses unique hydraulic mechanisms to fracture calcium and optimize luminal gain, and Stryker aims to expand its application to coronary disease.
Boston Scientific Corp Stock (BSX) Closed Up by 5.88% on May 18: Facts Behind the Movement
Boston Scientific Corp (BSX) stock closed up by 5.88% on May 18, driven by a strategic $1.5 billion investment in MiRus LLC, including an option to acquire its TAVR business. Further boosting investor confidence, the company initiated a $2 billion accelerated share repurchase agreement following strong Q1 2026 financial results that surpassed expectations. These actions, coupled with reaffirmed "Buy" or "Outperform" ratings from analysts, contributed to the significant upward movement despite some technical indicators suggesting caution.
A Look At Zimmer Biomet (ZBH) Valuation After 2026 Buyback Boost And Higher EPS Guidance
Zimmer Biomet Holdings (ZBH) has announced an increase in its 2026 share repurchase expectations to US$1.0 billion and raised its adjusted earnings per share forecast, leading to recent positive share price movement despite a weaker year-long performance. The stock, currently trading at US$83.70 with an estimated intrinsic value of US$102.95, is considered undervalued, driven by expectations of improved sentiment and future growth from strategic investments in digital health and robotics. However, potential risks like flat pricing and integration challenges could impact margins.
Stryker Corp. stock outperforms competitors on strong trading day
Stryker Corp.'s stock (SYK) increased by 2.11% to $313.22, outperforming its competitors on a mixed trading day. This marked the stock's fifth consecutive day of gains, despite the S&P 500 Index experiencing a slight decline. The Dow Jones Industrial Average, however, saw a gain.
Senseonics Holdings Inc (FRA:6L60) Stock Price, Trades & News
This page provides a comprehensive overview of Senseonics Holdings Inc (FRA:6L60), a medical technology company specializing in continuous glucose monitoring systems. It details the company's current stock price, financial strength, growth, momentum, liquidity, and profitability ranks, along with a business description and upcoming events. The report also highlights three severe warning signs detected by GuruFocus for the stock.
Stryker Corp. stock (US8636671013): quarterly results keep medical device demand in focus
Stryker Corp. continues to draw attention, as its latest quarterly earnings highlight strong demand for orthopedic implants and surgical equipment. The company's diverse portfolio, driven by aging populations and continuous product innovation, positions it as a key indicator for elective surgery trends and hospital spending. While benefiting from structural growth drivers, Stryker also navigates challenges such as reimbursement changes, regulatory requirements, and competitive pressures within the medical device sector.
North Dakota State Investment Board Invests $6.93 Million in Intuitive Surgical, Inc. $ISRG
The North Dakota State Investment Board has acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG), purchasing 12,238 shares valued at approximately $6.93 million. This comes amidst other hedge funds adjusting their stakes in the medical equipment provider, and various analyst reports and positive sentiment regarding Intuitive Surgical's integration of AI in healthcare and the performance of its da Vinci 5 system.
RiverFront Investment Group LLC Sells 4,777 Shares of Stryker Corporation $SYK
RiverFront Investment Group LLC reduced its stake in Stryker Corporation by 35.4% during the fourth quarter, selling 4,777 shares and now owning 8,719 shares valued at approximately $3.07 million. Despite this reduction, institutional ownership in Stryker remains high at 77.09%, and analysts maintain a "Moderate Buy" consensus rating with a target price of $395.48. The company recently missed EPS and revenue estimates but declared a quarterly dividend of $0.88 per share.
The Global Price of Progress: The Geography of Robotic Surgery
Robotic surgery is rapidly adopted in the U.S. and other wealthy nations but is significantly less accessible in low-income countries due to high costs and lack of infrastructure. This disparity creates a two-tiered healthcare system, leading to medical tourism for those who can afford it and potentially leaving patients in underserved areas with limited surgical options. The increasing competition from new robotic surgery systems post-patent expiration might eventually drive down costs, but it remains uncertain whether this will make the technology universally available.
AVS, Now Part of Stryker, Enrolls First Patient in First-in-Human Coronary Intravascular Lithotripsy Study
Amplitude Vascular Systems (AVS), now part of Stryker, has enrolled its first patient in the POWER CAD I study, a first-in-human coronary intravascular lithotripsy (IVL) study. This study will evaluate the feasibility of the Pulse IVL™ System to treat patients with severely calcified coronary arterial disease, marking a significant step in expanding the technology's application to coronary disease. The Pulse IVL system uses a unique hydraulic mechanism designed for efficient treatment of complex calcified lesions, aiming to improve patient outcomes in an evolving area of medicine.
Stryker stock (US8636671013): Results and product momentum remain in focus
Stryker's recent quarterly results continue to interest investors, reflecting ongoing demand for medical and surgical devices and serving as a bellwether for the broader medtech industry. The company's performance is closely watched for insights into elective procedure volumes, hospital spending, and operating trends in orthopedic and neurotechnology markets. With substantial revenue and broad-based demand, Stryker remains a key indicator of long-term healthcare demand and market rotations.
Bronstein, Gewirtz & Grossman, LLC Encourages Stryker Corporation (SYK) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Stryker Corporation (NYSE:SYK) stockholders following a significant drop in stock price. This decline occurred after Stryker reported a cyberattack in March 2026 that "meaningfully" affected its first-quarter 2026 operating results. The firm encourages affected investors to inquire about this securities investigation.
Is Stryker (SYK) At An Attractive Price After Recent Share Price Swings
Stryker (SYK) has experienced recent share price volatility, with a 7.5% rise over the last week but declines over the past month, year-to-date, and year. Simply Wall St's valuation checks currently give Stryker a score of 2 out of 6. A Discounted Cash Flow (DCF) analysis suggests Stryker is undervalued by 16.5% at an estimated intrinsic value of $367.59 per share, while its P/E ratio of 35.24x makes it appear overvalued compared to the industry average and Simply Wall St's Fair Ratio of 31.22x.
Staley Capital Advisers Inc. Has $11.76 Million Stake in Mercury Systems Inc $MRCY
Staley Capital Advisers Inc. significantly reduced its stake in Mercury Systems Inc. (NASDAQ:MRCY) by 60.8% in the fourth quarter, now holding 161,100 shares valued at $11.76 million. This reduction comes despite Mercury Systems reporting better-than-expected quarterly results with an EPS of $0.27 and revenue of $235.76 million, an 11.5% year-over-year increase. Insider selling by executives and directors has also been notable, with 472,383 shares sold over the last 90 days, while analysts maintain a "Moderate Buy" rating with a consensus target price of $89.89.
Thrivent Financial for Lutherans Increases Position in Stryker Corporation $SYK
Thrivent Financial for Lutherans significantly increased its stake in Stryker Corporation (NYSE:SYK) by 22.1% in the fourth quarter, bringing its total holdings to 119,191 shares valued at approximately $41.9 million. Several other institutional investors also increased their positions, with hedge funds and institutions collectively owning 77.09% of Stryker's stock. Despite some analysts trimming price targets due to weaker-than-expected quarterly results, the stock maintains a consensus "Moderate Buy" rating.
Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?
Fractyl Health (GUTS) saw a 14.0% stock increase following its Q1 2026 profitability shift to $9.22 million net income and authorization to begin human trials for its RJVA-001 GLP-1 gene therapy in the Netherlands. This development makes Fractyl a dual clinical-stage company, alongside its Revita procedure for weight maintenance. While the RJVA-001 authorization strengthens the long-term Rejuva gene therapy story, the Revita data and potential FDA filing in late 2026 remain the more immediate catalysts for the company.
Medtronic Shares Near One-Year Lows as NYSE Open Looms After Friday Drop
Medtronic (NYSE: MDT) shares closed Friday down 1.07% at $76.15, just above their 52-week low of $74.40, following a broader market pullback. Investors are now awaiting the company's fiscal Q4 and full-year earnings report on June 3. The stock's short-term outlook remains cautious, with analysts having recently trimmed price targets, and the recent MiniMed IPO raising questions about timing and valuation.
Inari Medical stock (US45332Y1092): Stryker deal reshapes outlook for thrombectomy specialist
Stryker's agreement to acquire Inari Medical for $4.8 billion has significantly altered the outlook for the thrombectomy specialist. The deal, which emphasizes minimally invasive treatments for venous thromboembolism, positions Inari Medical within a larger medtech group while capping its standalone stock upside. Investors are now focused on deal completion dynamics and the potential for synergy within Stryker's global network, as Inari continues to show strong revenue growth with its ClotTriever and FlowTriever systems.
Analysts Have Made A Financial Statement On Shoulder Innovations, Inc.'s (NYSE:SI) First-Quarter Report
Shoulder Innovations, Inc. (NYSE:SI) saw its shares surge 18% after its first-quarter report, with revenues of US$17m beating expectations. Analysts have updated their forecasts, projecting 2026 revenues of US$67.3m, a 25% improvement, and a reduction in losses to US$1.70 per share, despite a modest increase in loss per share forecasts. The consensus price target remained unchanged at US$21.25, indicating that growing revenues offset concerns about increasing losses.
Qsemble Capital Management LP Acquires 20,036 Shares of Stryker Corporation $SYK
Qsemble Capital Management LP significantly increased its stake in Stryker Corporation by 758.1% in the fourth quarter, purchasing 20,036 additional shares, bringing its total holdings to 22,679 shares valued at $7.97 million. Despite Stryker missing earnings expectations with EPS of $2.60 and revenue of $6.02 billion, analysts maintain a "Moderate Buy" rating with an average price target of $395.48, and the company announced a quarterly dividend of $0.88 per share. Other institutional investors also adjusted their positions, and insider selling by VP M Kathryn Fink was noted.
